NOTAL-OCT V.2.5 vs Commercial OCT in AMD Patients

Sponsor
Notal Vision Ltd. (Industry)
Overall Status
Completed
CT.gov ID
NCT03969303
Collaborator
Elman Retina Group (Other)
287
1
11.5
25

Study Details

Study Description

Brief Summary

Primary objective:

To evaluate the level of agreement between the NOTAL-OCT V2.5 and a commercial OCT in the presence of fluid as identified in the OCT images, in the central 10 degrees of the macula in AMD (Age-related Macular Degeneration) patients.

Secondary objectives:
  1. To evaluate the level of agreement between the NOTAL-OCT V2.5 and a commercial OCT in the presence of fluid as identified in the OCT images, in the central 10 degrees of the macula in DME (Diabetic Macular Edema) patients.

  2. To evaluate patient experience when self-operating the Notal-OCT V2.5.

Condition or Disease Intervention/Treatment Phase
  • Device: Notal Vision Optical Coherence Tomography Device Version 2.5 (NOTAL-OCT V2.5)

Detailed Description

To evaluate the sensitivity and specificity regarding the presence and absence of fluid on OCT images of AMD patients. OCT images from the central 10 degrees of the macula in AMD patients will be obtained using the NOTAL OCT v.2.5 and a commercial OCT device (Zeiss Cirrus / Heidlberg SPECTRALIS). These images will be evaluated for the presence/absence of fluid in the images by a human grader. The sensitivity and specificity will be determined by comparison of the presence/absence of fluid in the NOTAL OCT v2.5 images with the presence/absence of fluid in the commercial OCT images.

To evaluate the sensitivity and specificity regarding the presence and absence of fluid on OCT images of DME patients. OCT images from the central 10 degrees of the macula in DME patients will be obtained using the NOTAL OCT v.2.5 and a commercial OCT device (Zeiss Cirrus / Heidlberg SPECTRALIS). These images will be evaluated for the presence/absence of fluid in the images by a human grader. The sensitivity and specificity will be determined by comparison of the presence/absence of fluid in the NOTAL OCT v2.5 images with the presence/absence of fluid in the commercial OCT images.

Patients will complete a questionnaire regarding the usability of the NOTAL-OCT v.2.5 device

Study Design

Study Type:
Observational
Actual Enrollment :
287 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Comparison Between Retinal Images Captured by NOTAL-OCT V2.5 and Zeiss Cirrus / Heidelberg Spectralis SD OCT - Study Protocol
Actual Study Start Date :
Oct 20, 2018
Actual Primary Completion Date :
Jul 11, 2019
Actual Study Completion Date :
Oct 4, 2019

Arms and Interventions

Arm Intervention/Treatment
NOTAL OCT v.2.5 and Commercial OCT on AMD Patients

OCT Images will be obtained in the central 10 degrees of the macula in AMD patients using the NOTAL OCT v.2.5 device and a Commercial device (Zeiss Cirrus/Heidelberg SPECTRALIS).

Device: Notal Vision Optical Coherence Tomography Device Version 2.5 (NOTAL-OCT V2.5)
OCT SCAN

Outcome Measures

Primary Outcome Measures

  1. Comparison of presence/absence of fluid on OCT images from NOTAL-OCT v.2.5 device with a commercial OCT device, in AMD (Age-related Macular Degeneration) patients [less than an hour]

    To evaluate the sensitivity and specificity regarding the presence and absence of fluid on OCT images of AMD patients. OCT images from the central 10 degrees of the macula in AMD patients will be obtained using the NOTAL OCT v.2.5 and a commercial OCT device (Zeiss Cirrus / Heidlberg SPECTRALIS). These images will be evaluated for the presence/absence of fluid in the images by a human grader. The sensitivity and specificity will be determined by comparison of the presence/absence of fluid in the NOTAL OCT v2.5 images with the presence/absence of fluid in the commercial OCT images.

Secondary Outcome Measures

  1. Comparison of presence/absence of fluid on OCT images from NOTAL-OCT v.2.5 device with a commercial OCT device, in DR (Diabetic Retinopathy) patients [less then an hour]

    To evaluate the sensitivity and specificity regarding the presence and absence of fluid on OCT images of DR patients. OCT images from the central 10 degrees of the macula in DR patients will be obtained using the NOTAL OCT v.2.5 and a commercial OCT device (Zeiss Cirrus / Heidlberg SPECTRALIS). These images will be evaluated for the presence/absence of fluid in the images by a human grader. The sensitivity and specificity will be determined by comparison of the presence/absence of fluid in the NOTAL OCT v2.5 images with the presence/absence of fluid in the commercial OCT images.

  2. Patient experience using the NOTAL-OCT v.2.5 device [less than an hour]

    Patients will complete a questionnaire with 13 statements or questions regarding the usability of the NOTAL-OCT v.2.5 device. For the first 10 statements, patients are asked to specify a level of agreement to the statement. The scale is named "Level of Agreement" and ranges from 1 = strongly agree, to 5 = strongly disagree. A patient's indicating a value of 1 is considered to be a better outcome. The remaining 3 questions are free-form.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Ability and willingness to give informed consent (IC)

  • 18 years of age or older

  • Diagnosis of AMD (age-related macular degeneration) and/or DME (diabetic macular edema) in the study eye as confirmed by the investigator and recorded in the patient's clinical record

  • Ability to undergo OCT (optical coherence tomography) testing

  • Visual acuity of 20/400 Snellen (6/120) or better in the study eye

Exclusion Criteria:
  • Any ophthalmic or systemic condition that in the opinion of the investigator would preclude the patient from participating in the study.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Elman Retina Group, PA Baltimore Maryland United States 21237

Sponsors and Collaborators

  • Notal Vision Ltd.
  • Elman Retina Group

Investigators

  • Principal Investigator: Michael Elman, Michael Elman, M.D. 9114 Philadelphia Rd #310 Baltimore, Maryland 21237

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Notal Vision Ltd.
ClinicalTrials.gov Identifier:
NCT03969303
Other Study ID Numbers:
  • C2018.008
First Posted:
May 31, 2019
Last Update Posted:
Nov 12, 2020
Last Verified:
Oct 1, 2020
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 12, 2020